Comparative Pharmacology
Head-to-head clinical analysis: MYTELASE versus RAZADYNE ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYTELASE versus RAZADYNE ER.
MYTELASE vs RAZADYNE ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mytelase (ambenonium chloride) is a reversible acetylcholinesterase inhibitor that increases acetylcholine concentration at cholinergic synapses by inhibiting its hydrolysis. This enhances neuromuscular transmission and improves muscle strength.
Reversible, competitive acetylcholinesterase inhibitor, increasing acetylcholine concentrations in the synaptic cleft of the central nervous system, particularly enhancing cholinergic neurotransmission in the cerebral cortex and hippocampus.
Oral: 5–25 mg three times daily; maximum 100 mg/day. IV: 2–5 mg every 2–4 hours as needed for myasthenic crisis.
16 mg orally once daily in the morning; may increase to 24 mg once daily after minimum of 4 weeks; maximum dose 24 mg/day.
None Documented
None Documented
3-4 hours (short; requires frequent dosing every 3-4 hours for myasthenia gravis management).
Terminal half-life approximately 7-8 hours; clinical context: supports twice-daily dosing
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal excretion (<5%).
Renal: 95% as unchanged drug and metabolites; Fecal: 5%
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor